ciqorin 100 mg mīkstās kapsulas
teva pharma b.v., netherlands - ciklosporīns - mīkstās kapsulas - 100 mg
itraconazol actavis 100 mg cietās kapsulas
teva b.v., netherlands - itrakonazols - kapsula, cietā - 100 mg
azithromycin krka 500 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - azitromicīns - apvalkotās tabletes - 500 mg
clarithromycin-teva 500 mg apvalkotās tabletes
teva pharma b.v., netherlands - klaritromicīns - apvalkotā tablete - 500 mg
klerimed 250 mg apvalkotās tabletes
medochemie ltd., cyprus - klaritromicīns - apvalkotā tablete - 250 mg
klerimed 500 mg apvalkotās tabletes
medochemie ltd., cyprus - klaritromicīns - apvalkotā tablete - 500 mg
azithromycin teva 500 mg disperģējamās tabletes
teva pharma b.v., netherlands - azitromicīns - disperģējamā tablete - 500 mg
fromilid 500 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - klaritromicīns - apvalkotā tablete - 500 mg
rybrevant
janssen-cilag international n.v. - amivantamab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.